<DOC>
	<DOCNO>NCT02700932</DOCNO>
	<brief_summary>This open-label , multi-center study . Subjects study receive eight ( 8 ) treatment 11±5 week ( 6-16 week ) interval , PicoWayTM device use 1064 nm/ 785±20 nm/ 532 nm handpiece accord study protocol ( tattoo color ) . Subjects return one follow‐up ( FU ) visit clinic 8 week follow last treatment . Methodology describe protocol evaluate efficacy safety treatment carry visit clinic</brief_summary>
	<brief_title>Clinical Study Evaluate Performance PicoWayTM 1064 nm/ 785 nm/ 532nm Picosecond Laser Tattoo Removal</brief_title>
	<detailed_description>This study prospective clinical study demonstrate safety efficacy PicoWayTM device tattoo removal . Up total 60 healthy candidate seek tattoo removal clearance treatment participate investigator enrol 3 participate study site . Subjects receive eight ( 8 ) PicoWayTM treatments 11±5 ( 6-16 ) week 's interval . Prior consecutive treatment , investigator decide , base degree clearance assessment , subject undergo additional treatment forward 8 week Follow-Up visit treatment . Topical anesthetic ( ointment ) intradermal inject solution may use prior treatment . Each subject follow one post treatment visit conduct : • Eight week post last treatment - 8wk FU .</detailed_description>
	<criteria>1 . Healthy female male subject 18 70 year age 2 . Fitzpatrick skin type IVI 3 . Have unwanted decorative ( noncosmetic ) tattoo ( ) willing undergo laser treatment remove 4 . Have least one follow color tattoo : black , green and\ blue . 5 . Willing receive propose PicoWayTM treatment comply study ( protocol ) requirement 6 . Willing photograph image take treated area use evaluation , publication presentation ( subject identity mask ) 7 . For female subject : pregnant lactate either postmenopausal , surgically sterilize , use medically acceptable form birth control least 3 month prior enrollment ( i.e. , oral contraceptive , contraceptive implant , barrier method spermicide abstinence ) 8 . Informed consent process complete subject consent sign 1 . Pregnant plan become pregnant , give birth le 3 month ago , and/or breast feeding 2 . Hypersensitivity light exposure 3 . Active sun tan 4 . Suffering significant skin condition treat area inflammatory skin condition , include , limited , open laceration abrasion , hidradenitis , dermatitis treatment area prior treatment ( duration resolution per Investigator 's discretion ) treatment course 5 . Have history squamous cell carcinoma melanoma 6 . History keloid scarring , abnormal wound heal / prone bruise 7 . Use oral isotretinoin ( Accutane® ) within 12 month initial treatment plan use course study . Note : Skin must regain normal degree moisture prior treatment , e.g. , lack noticeable skin flaking , skin peel skin surface roughness . 8 . History immunosuppression/immune deficiency disorder ( include HIV infection AIDS ) currently use immunosuppressive medication 9 . Known allergy lidocaine , tetracaine , Xylocaine epinephrine 10 . As per investigator 's discretion , physical mental condition might make unsafe subject participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>non-invasive</keyword>
</DOC>